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Abstract
Background: Patients with major depression refractory to repeated pharmacological trials (TRD)
may remain symptomatic for many years after their index episode. Augmentation strategies (with
lithium or an atypical antipsychotic) or combining an antidepressant with short-term psychotherapy
have been used with relative success in these patients. The aim of this study was to assess the
effectiveness of the concomitant administration of quetiapine, an atypical antipsychotic, or placebo,
to cognitive-behavior therapy (CBT) in TRD.
Methods: Thirty-one patients who met entrance criteria for unipolar major depression (TRD
stage II or greater) underwent 3 weeks of lithium augmentation after which non-responders (N =
22) were randomized to receive either quetiapine or placebo as an adjunct to their 12 weekly CBT
sessions (quetiapine/CBT or placebo/CBT groups). Primary efficacy measures were the Hamilton
and the Montgomery-Asberg rating scales for depression.
Results: Overall, there was a significant reduction in both primary efficacy measure scores at
LOCF for the 11 patients in the quetiapine/CBT group but not in the placebo/CBT treated patients.
Patients in the quetiapine/CBT group, compared to those receiving placebo/CBT, showed a
significantly greater degree of improvement on one primary and one secondary efficacy measure,
were more likely to complete the trial and, completed a greater number of CBT sessions.
Conclusion:  Although preliminary, our results suggest that the adjunctive administration of
quetiapine to CBT may prove useful in the treatment of stage II TRD.
Trial Registration: Current Controlled Trials ISRCTN12638696.
Background
Many depressed patients fail to respond to an adequate
treatment with a single or, to several antidepressant trials,
constituting what can be generally termed treatment
refractory depression (TRD) [1]. The 'Sequenced Treat-
ment Alternatives to Relieve Depression (STAR*D)' study
has shown that only 50 to 55% of patients attain remis-
sion, defined by a Hamilton Rating Scale for Depression
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(HRSD) score of 7 or less, following the sequential admin-
istration of two antidepressant treatments [2].
The high degree of impairment and suffering imposed by
TRD has led clinicians to search for an ever-increasing
array of effective treatment strategies. Augmentation (with
lithium carbonate or an atypical antipsychotic), switching
to an antidepressant from a different class, combining sev-
eral different antidepressants or an antidepressant with
short-term psychotherapy, has been used with relative
success in these patients [2-9]. Continued unresponsive-
ness despite persistent treatments has lead to the develop-
ment of classification schemes for TRD [1,10]. Stage II
TRD for instance is defined by the failure of two prior anti-
depressant treatments, each from a different class [1,10].
Quetiapine, an atypical antipsychotic with a broad spec-
trum of use including anti-anxiety and mood stabilizing
properties, has proved useful as mono therapy in bipolar
depression and, as adjunctive SSRI treatment in major
depression [11-14]. As, by definition, patients in stage II
TRD are refractory to the standard antidepressants, assess-
ing quetiapine's potential benefit in these patients was
thus of interest. Additionally, cognitive-behavior therapy
(CBT) has been shown to result in outcomes 'generally
comparable' to those of patients randomly assigned to
alternative pharmacological strategies following an unsat-
isfactory response to prior treatment with the selective
serotonin reuptake inhibitor (SSRI) citalopram [9]. This
suggests that CBT may be of use in stage II TRD. Such a
finding would not only be pertinent in TRD but also, in
the treatment of depressed patients where medication
may pose a health risk, such as during pregnancy or in the
aged.
The aim of this study was to assess the effectiveness of the
concomitant administration of quetiapine or placebo to
patients receiving CBT in stage II (or greater) TRD.
Methods
Subjects
Study design and patient flow are depicted in Figure 1.
Overall, 40 patients underwent a preliminary evaluation
for entry into this study. Three signed informed consent
forms but refused to enter into the screening phase of the
trial whereas 6 were judged not to suffer from a major
affective disorder and were excluded. The remaining 31
patients ranged in age from 23 to 66 and were recruited
from the psychiatric outpatient service (N = 12), the psy-
chiatric emergency service (N = 5), their family physicians
(N = 12) or psychologists (N = 2). Patients met DSM-IV
criteria for unipolar major depression with a HRSD (21
items [15]) score of ≥ 20 at screen and of ≥ 18 at both days
21 and 28 (randomization). A Clinical Global Impression
severity scale (CGI-S, [16]) score of 4 or more at all three-
evaluation points was also required.
Treatment refractoriness, verified by examining any perti-
nent medical records or charts, was determined by the fail-
ure of 2 (or more) 8-week treatments with 2 different
classes of antidepressants. In addition, for at least 3 of
these eight weeks, doses were required to be at or near the
highest therapeutically recommended doses [17,18]. In
27 of the above patients venlafaxine was judged to have
been sufficiently administered to constitute an adequate
trial (225 mg/day, N = 19; 300 mg/day, N = 6; 375 mg/day
N = 2). Citalopram was prescribed in 14 of these 27
patients (40 mg, N = 8, ≥ 50 mg, N = 6). Other individual
antidepressants were prescribed much less frequently (N
values from 1 to 5). Although 5 patients received sertra-
line and 5 paroxetine, 3 from each of these latter two
groups received less that the highest recommended dose
(150 rather than 200 mg and 40 rather than ≥ 50 mg,
respectively). All other treatments (fluoxetine, mirtazap-
ine, nefazodone, phenelzine, tricyclic antidepressants,
moclobemide, bupropion) followed the standard dosing
recommendations (Table 1, footnote f). Overall, these
dose ranges were equivalent to those shown to induce
remission (or response) in the STAR*D study [2].
Primary exclusion criteria included patients with a current
risk of suicide, women of childbearing potential who were
pregnant (or planning pregnancy), breast-feeding or not
using medically adequate means of birth control for 3
months prior to admission into the study. Also excluded
were patients with a DSM-IV diagnosis of bipolar disor-
der, schizophrenia, personality disorder (borderline, anti-
social, schizoid, schizotypal or paranoid), panic,
generalized anxiety, obsessive-compulsive, somatoform
or organic mental disorder, anorexia nervosa, bulimia or
those with definite or suspected substance abuse in the
previous 12 months. Although exclusion was primarily
based upon the clinical interview, whenever possible, sup-
plementary medical documentation, including hospital
charts, were reviewed. Patients requiring concurrent treat-
ment with any psychotropic medication other that that
permitted in the trial (zopiclone or temazepam as hypno-
tics on a PRN basis) or those with serious or unstable
medical illnesses, known psychotropic drug allergies or
co-existing diseases or treatments that might contraindi-
cate the use of the study drug were also excluded.
The study was conducted at 2 sites in close proximity to
one another (by the same investigators) in Canada and
was approved by both a University and an Independent
Institutional Review Board. After the study was com-
pletely described to the patients written informed consent
was obtained in accordance with the Helsinki Declara-
tion.BMC Psychiatry 2008, 8:73 http://www.biomedcentral.com/1471-244X/8/73
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Study design and patient flow Figure 1
Study design and patient flow.
assessed for eligibility  (N = 40)
refused to participate  (N = 3)
did not meet entrance criteria (N = 6)
entered screen  (N = 31), day 0
21 days of lithium augmentation + AD treatment (N = 29)
lithium responders  (N = 5)
screen failures  (N = 2)
eligibility for randomization, day 21 (N = 24)
lithium and AD taper
refused to taper (N = 2)
randomization, day 28 (N = 22)
placebo/CBT (N = 11) quetiapine/CBT (N = 11) Assessments
day 35
day 42
day 49
day 56
day 70
day 84
day 98
day 112
Completed all CBT sessions, (N = 5) Completed all CBT sessions, (N =10)
Table 1: Patient demographic and clinical characteristics.
Q+CBT
(N = 11)
P+CBT
(N = 11)
All patients
(N = 31)
Women 8 (73%) 8 (73%) 23 (74%)
Average age 41.6 ± 13 44.9 ± 10 43.7 ± 11
Average # of treatments*f 3 ± 1 3 ± 1 3 ± 1
Average onset of depression 21 ± 15 mo 24 ± 15 mo 22.7 ± 16 mo
Prior augmentation ** 4 (36%) 4 (36%) 11 (35%)
Prior ECT*** 1 1 2
Mean HADS at screen 30 ± 6.4 29.8 ± 6.7 28.4 ± 6.7
Mean HRSD at screen 23.4 ± 3 22.4 ± 4.7 23 ± 3.5
Mean MADRS at screen 30.5 ± 3 29.8 ± 5 30.7 ± 4
Mean CGI at screen 4.2 ± 0.4 4.2 ± 0.4 4.2 ± 0.4
* Although patients had, on average, 3 adequate antidepressant trials (see f) many also received antidepressants at lower dosages than those 
described below.
f Therapeutically recommended daily doses were; venlafaxine, 225 mg/350 mg (moderate, severe depression, respectively), citalopram 40 mg, 
sertraline 200 mg, mirtazapine 45 mg, nefazodone 600 mg, paroxetine 50 mg, amitriptyline 300 mg, phenelzine 90 mg [17,18].
** With either lithium carbonate or an atypical antipsychotic.
*** Electroconvulsive therapy.BMC Psychiatry 2008, 8:73 http://www.biomedcentral.com/1471-244X/8/73
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Study design
Patients underwent a screen evaluation where a complete
psychiatric history, including previous and current phar-
macological therapy, was obtained. A physical examina-
tion was performed along with an electrocardiogram.
Weight, height, blood pressure (sitting and standing) and
pulse were recorded and blood samples were drawn for
routine blood biochemistry (liver enzymes, creatinine,
electrolytes, calcium, glucose and prolactin), hematology
(hemoglobin, hematocrit, RBC, WBC, differential and
platelets) and endocrinology (TSH, serum pregnancy
test). A urine sample for analysis and drug screen was
taken.
Evaluator-rated scales at screen included the HRSD and
the Montgomery-Asberg Depression Rating Scale
(MADRS, [19]), which constituted the primary efficacy
measures. Secondary efficacy measures at screen included
the investigator-rated Clinical Global Impression, severity
and improvement (CGI-S, CGI-I), the Extra-pyramidal
Symptom Rating Scale (ESRS, [20]) and the Barnes' Aka-
thisia Rating scale (BAS, [21]). Patient-rated secondary
efficacy measures at screen were the Hospital Anxiety and
Depression Scale (HADS, [22]) and the Quality of Life
Enjoyment and Satisfaction Questionnaire (Q-LES-Q, 16
question version, [23]).
Patients who continued to meet study entrance criteria
underwent an initial 3-week open phase of lithium aug-
mentation (≥ 600 mg per day, serum levels of between 0.6
and 0.9 mEq/L by day 7) of their antidepressant treatment
(using therapeutically recommended doses). HRSD scores
were reassessed at day 21 and patients with a ≥ 40% reduc-
tion (or a score < 18) were classified as responders and
excluded. Non-responders were tapered of their medica-
tion (lithium and antidepressant) during an 8-day period
and reassessed for randomization at day 28 (week 4).
Those with a HRSD of ≥ 18 were randomized to one of
two treatment groups; placebo and CBT (placebo/CBT) or
quetiapine and CBT (quetiapine/CBT).
Randomization
Subjects were randomized strictly sequentially. If a subject
discontinued from the study, the subject number was not
reused, and the subject was not allowed to re-enter the
study. Individual treatment codes were in sealed enve-
lopes (code-breaks, indicated the treatment allocation
corresponding to a blinded drug blister pack) for each ran-
domized patient. These were provided by AstraZeneca
IPS(UK). AstraZeneca Canada Inc kept one set of code
envelopes. The investigator kept a second set.
Treatment
CBT was administered in 12 weekly ≥ one-hour sessions
given in an individual setting by the same therapist (an
MSc level psychologist with over 7 years of clinical experi-
ence supervised by a PhD level psychologist specialized in
CBT). Individual, rather than group CBT treatment was
chosen as there is evidence to suggest that the latter may
be less efficacious than individually administered CBT in
alleviating depressive symptoms [24]. The CBT paradigm,
modified from that used in a previous study [24], was
largely based upon the Beck cognitive therapy model with
its associated behavioral techniques [25]. In addition,
social skills training and applied relaxation training was
also administered [26,27]. Homework assignments were,
whenever possible kept in record form and monitored by
the therapist at the following session.
Medication was administered orally with an initial dose of
12.5 mg for quetiapine and placebo, twice daily. Quetiap-
ine was titrated up to a maximum of 200 mg twice daily
within the first 14 days following randomization using a
flexible dose schedule dependent upon the patient's clin-
ical response and the side-effects profile. The dose
remained stable thereafter. Compliance was monitored by
capsule counts of returned medication at each visit.
Assessments
Safety (vital signs, weight, adverse events) assessments
were performed weekly up to week 8 (day 56) and once
every 2 weeks thereafter. Electrocardiograms were
repeated at randomization (week 4) and midway through
the active phase of the study (week 10). Hematology, bio-
chemistry, and urine analysis were repeated at the final
visit (week 16). The following rating instruments (HRSD,
MADRS, CGI-S and CGI-I) were performed again at weeks
3 and 4 and at every two weeks thereafter. The EPS scale,
the BAS, the HADS and Q-LES-Q were repeated at week 16
or at LOCF following randomization.
Statistical analysis
The statistical analysis package Systat (Version 11) was
used for power and, for statistical analysis. Given the
study population the trial was designed to detect a mod-
erate effect, such as a 5 to 6 point reduction of the HRSD.
Several scenarios were run with initial HRSD scores of
between 20 and 25 at screen, scores not unreasonable for
this type of population. Results suggested that a mini-
mum of 9 to 10 patients randomized to each treatment
group were needed in order to yield sufficient power (80%
to 90%) to detect a within group effect (alpha set at 0.05).
The safety analyzable population was defined as all
patients who received at least one dose of either lithium
carbonate (N = 30) or of study drug (N = 22). The intent-
to-treat population (ITT), used for efficacy analyses, con-
sisted in all baseline patients who were randomized and
took at least one dose of study drug and who had at least
one post-randomization assessment (N = 22). All efficacyBMC Psychiatry 2008, 8:73 http://www.biomedcentral.com/1471-244X/8/73
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analyses used either last observation carried forward
(LOCF) or data on patients available at each study visit.
Baseline comparability of the two treatment groups for
demographic and clinical variables was assessed by two-
sample t-tests for continuous variables and the X2 test for
categorical variables. Response was defined as above
(HRSD score reduction of ≥ 40% or a score of < 18).
Within group efficacy analyses were performed using two-
sample t-tests for paired variables. Between group efficacy
analyses were performed using analysis of covariance
(ANCOVA) using change from baseline as the dependent
variable and baseline measurements as the covariate.
Results
Lithium carbonate administration in TRD
Clinical and demographic variables for the screened and
for the randomized patients are detailed in Table 1. Of
note is a prior history of electroconvulsive treatment (2
patients, one in each randomized group) suggesting that
some patients had greater than stage II refractory depres-
sion. Patient sub-samples were not significantly different
with regards sex, age, duration of illness, prior antidepres-
sant treatment (for the current episode) and initial rating
scale scores from the pooled values of the 31 patients ini-
tially screened for the study. Of the 31 patients screened,
one was withdrawn prior to the lithium augmentation
phase due to a urine test positive for drugs of abuse. A sec-
ond patient was withdrawn during the augmentation
phase due to lithium non-compliance, leaving 29 compl-
eters of this open phase of the study. Of these latter
patients 5 (17%) were classified as lithium responders
(HRSD of 23 ± 4 at screen, 12.4 ± 2.3 at day 21) and were
subsequently withdrawn from the study. Two patients
classified as lithium non-responders withdrew consent no
longer wishing to taper their concomitant antidepressant
treatment. Twenty-two patients were thus randomized to
the CBT portion of the trial.
Quetiapine and CBT administration versus placebo and 
CBT in TRD
Primary efficacy measures were significantly (p < 0.05, t-
test for paired values) improved in patients randomized
to quetiapine/CBT (HRSD 23.5 ± 3 at randomization, 16
± 5 at LOCF; MADRS of 30.5 ± 3 at randomization, 22 ± 7
at LOCF). In contrast, no significant improvement in was
observed in the placebo/CBT group. Results for the sec-
ondary efficacy measures mimicked those of the primary
efficacy measures, as shown in Table 2. Only two of the
four secondary efficacy measures (CGI-S and CGI-I)
showed statistical improvement in the placebo/CBT
group.
Significant between group differences (ANCOVA using
baseline rating scores as covariates and LOCF scores as
outcome) were observed between the two treatment
groups with regards one primary (HRSD, p < 0.05) and
one secondary efficacy measure (Table 2). An interesting
between group observation was study completion (the
number of patients completing the study versus the
number of dropouts). Ten of 11 patients in the quetiap-
ine/CBT group completed the trial whereas 5 of 11 com-
pleted the study in the placebo/CBT group. This was
reflected in a significant difference in the number of com-
pleted CBT sessions between the 2 groups (p < 0.05,
ANOVA, mean number for the quetiapine/CBT group was
11 ± 2, the mean for the placebo/CBT group was 7 ± 5).
Of note is that the 5-placebo/CBT completers showed a
statistically significant reduction in both primary rating
scale scores at LOCF (HRSD 22 ± 1.4 versus 15 ± 2.3 p <
0.01, MADRS 31 ± 2.6 versus 19 ± 2.4, p < 0.01, t-test for
paired values).
The average dose of quetiapine attained within the first 14
days following randomization was lower than that typi-
cally used in the treatment of chronic psychosis (147.7 ±
112 mg/day, range of 25 to 375 mg). Patients in the pla-
cebo/CBT group had a slightly higher average dose (209.1
± 120 mg/day, range 50 to 400 mg), although the differ-
ence was not statistically significant. The average number
of pills per day for both groups was similar (1.9 ± 0,6 pills
per day for quetiapine/CBT, 2.1 ± 0,7 for placebo/CBT).
Quetiapine was well tolerated with an adverse event pro-
file from mild to moderate. A non-significant increase in
body weight was observed in both groups. No serious
adverse events were observed and no patient withdrew
due to a drug-induced event. One patient (quetiapine
group) was withdrawn due to a possible anomaly detected
at the week 10 electrocardiogram that was ultimately
found to be a false positive result. Common quetiap-
ine(n)/placebo(n) related adverse events were somno-
lence (7/1), insomnia (5/2), headache (4/1), dry mouth
(4/1), nausea (2/2) gastrointestinal discomfort (2/3) and
Table 2: Percent improvement of secondary rating scale scores
Q+CBT
(N = 11)
P+CBT
(N = 11)
Between group 
differences
HADS 20%a 6% ns
CGI-S 33%c 12%a ns
CGI-I 33%c 23%a ns
Q-LES-Q 29%b 2% p < 0.05d
a p < 0.05, t-test for paired values comparing screen (or 
randomization) and LOCF scores for individual rating scales within 
each group.
b p < 0.01, t-test for paired values comparing screen and LOCF scores 
for the Q-LES-Q rating scale within each group.
c p < 0.005, t-test for paired values comparing screen (or 
randomization) and LOCF scores for individual rating scales within 
each group.
d ANCOVA using screen scores as covariates and LOCF scores as 
outcome.BMC Psychiatry 2008, 8:73 http://www.biomedcentral.com/1471-244X/8/73
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labile hypertension (1/1). Only somnolence was found to
be statistically significant between treatment groups (p <
0.01, Fisher's exact test). Although one patient (placebo
group) was observed to suffer from mild akathesia and
muscle rigidity, overall, no significant changes were seen
in the BAS or EPSS scales in either group at LOCF.
Discussion
Our results suggest that quetiapine/CBT is more effective
that placebo/CBT in TRD. Although preliminary, these
results are compatible with both clinical and pre-clinical
evidence suggesting that quetiapine is a broad spectrum
antipsychotic potentially useful in treating bipolar (in
mono therapy form) and unipolar (as an adjunct to a
standard SSRI) depression [11-14]. Whether quetiapine
mono therapy would have yielded similar results remains
to be determined. In this trial it was solely administered as
an adjunct to CBT and CBT (mono therapy or combined
with pharmacotherapy) has been successfully used in
uncomplicated depression, residual and chronic depres-
sion [9,28-31]. In the present study, placebo/CBT patients
had a very high dropout rate. Completers however
showed reductions in primary rating scale scores equal to
those in the quetiapine/CBT group.
The average percent reductions of both primary rating
scale scores in the quetiapine/CBT group, although signif-
icant, were admittedly modest (30%). Although a differ-
ent psychotherapeutic modality was used, Keller et al.,
[28] reported a 73% response rate (remission and satisfac-
tory response) for the combined psychotherapy/antide-
pressant treatment of 'chronic' depression. However,
those with a satisfactory response only (a HRSD ≤ 15) rep-
resented about half of these patients and overall, 16 to 20
CBT-analysis system sessions were administered [28].
The modest rates reported here can be explained in several
ways. First, a lower overall (17%) response rate to lithium
augmentation was also observed. Interestingly, although
this rate is substantially lower than that typically reported
for lithium augmentation in patients following single
pharmacological trials [3,4] it was nevertheless almost
identical to that reported for patients not responding to
several prior antidepressant treatments [32]. It is therefore
possible that the modest results achieved by both active
treatments in this study (lithium, quetiapine/CBT) are
partially related to the high number of prior pharmaco-
logical trials our patient sample received. Second, this
study was a preliminary one and was designed to measure
response, rather than maximal response or remission. It is
possible that the number of CBT sessions administered
(12 sessions) and the time frame used in the lithium aug-
mentation phase (3 weeks) of the study were suboptimal.
Shapiro et al., [33] observed no significant difference
between an 8 and a 16 week CBT protocol in the treat-
ment of depression. However, a meta-analytic review of
several short-term psychotherapies for depression sug-
gests that a minimum of 13 sessions may be required in
order to approach what might be termed maximum ben-
efit [31]. In addition, although lithium augmentation can
be efficacious within 48 hours of its administration [4]
delayed responses (up to 8 weeks) have also been fre-
quently observed [3]. Therefore, longer durations of both
lithium and quetiapine/CBT treatments might have
resulted in a greater number of patients responding. It
may also have revealed more improvement in the pla-
cebo/CBT group. In this same light, the present study used
a flexible dose schedule of quetiapine that was in part
based upon patient input. In contrast to the standard anti-
depressant drugs, a recommended 'effective' quetiapine
dose was simply not available. Therefore, although our
average dose approximated that found to be efficacious as
an adjunct to SSRI treatment in non-bipolar depression
[13] it was much lower than the mono therapy fixed-
doses used to treat bipolar depression [12]. Higher doses
may have resulted in a greater response. Indeed, these
methodological considerations represent one of this
study's main limitations.
Third, entrance criteria for the present study were rela-
tively stringent and should have helped reduce the pla-
cebo-expectancy response rate [34]. Stage II TRD was the
baseline although some patients were closer to stage V
[1,10]. Patients had an average HRSD score ≥ 22 at both
screen and randomization (28 days later). An effort was
made to eliminate patients with severe or obvious co-
morbid psychiatric diagnoses. In addition, the time course
of this trial was quite long. For instance, there was a min-
imum 28-day period from screen to randomization. More
typically, up to an additional week was required in order
to verify all previous medication. Patients were seen and
assessed weekly during the open label phase of the trial.
As such, any possible early, non-specific therapeutic effect
produced by this intensive follow-up might have dissi-
pated by randomization (primary rating scale scores for
the 22 randomized patients were almost identical at
screen and randomization). These patients may have thus
represented a more homogeneous (or endogenous) group
than those typically reported in CBT studies of depression
and chronic depression [9,28,31]. Although the relation-
ship between the efficacy of CBT and the initial severity of
the depressive syndrome (inversely correlated) is still
unclear [30,33,35,36], such a phenomenon may have also
contributed to the overall low level of response, especially
in the placebo/CBT arm of the study.
The results of clinical trials where a much greater number
of patients were treated suggest that a combination 'phar-
macotherapy/psychotherapy' approach may be superior
to either treatment alone (or with placebo) in difficult toBMC Psychiatry 2008, 8:73 http://www.biomedcentral.com/1471-244X/8/73
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treat depression [9,28]. Our data neither contradicts this
contention nor supports it. Assessing the antidepressant
effectiveness of quetiapine mono therapy in similarly ill
patients would provide a more definitive answer. Our
results, as well as the increasing number of off-label indi-
cations for quetiapine [11,12,14,37] would certainly pro-
vide a reasonable premise for such an undertaking.
Quetiapine (but not haloperidol) has been shown to
improved cognitive skills in chronic psychotic patients
[38]. Therefore, factors other than (or in addition to) an
antidepressant effect might also have contributed to
quetiapine's effectiveness in our study. These could also
include non-specific sedative effects that might have influ-
enced our results by helping to stabilize patients during
the antidepressant withdrawal phase, better permitting
them to focus on the tasks at hand. The absence of this
effect in the placebo/CBT group may have contributed to
the high dropout rate and, as a consequence, the relatively
poor improvement in this group. This may have been at
least partially responsible for the very low dropout rate
and the better performance of the combined treatment
group.
Conclusion
The relatively small number of patients in this trail as well
as the many methodological considerations mentioned
above precludes a broad generalization of our results.
Nevertheless, we provide preliminary evidence that com-
bined quetiapine/CBT treatment may offer a clinically
pertinent alternative for patients with stage II TRD. This
finding is consistent with evidence suggesting that both
treatment modalities are evolving into broad spectrum
strategies useful in the treatment of pathologies ranging
from anxiety, personality and eating disorders, uncompli-
cated, chronic or bipolar depression and schizophrenia
[9,24,28,29,39-41].
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